Global Multiple Sclerosis Therapeutics Market Growth (Status and Outlook) 2024-2030

2024

Global Multiple Sclerosis Therapeutics Market Growth (Status and Outlook) 2024-2030

Name: Global Multiple Sclerosis Therapeutics Market Growth (Status and Outlook) 2024-2030
Brand: Bonafide Research
SKU: 95001205
Price: 3450 USD
Availability: InStock
Rating: 5 (18.5 reviews)

The global Multiple Sclerosis Therapeutics market, valued at US$ 16,660 million in 2024, is growing as demand increases for innovative therapies for multiple sclerosis management.

Bonafide Trust
10-09-2024
Pages : 89
Figures : 79
Tables : 93
Region : Global
Category : Lifescience & Healthcare
Pharmaceutical

Schedule a Call

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

The global multiple sclerosis therapeutics market has experienced substantial growth in recent years, driven by increasing awareness of the disease, advancements in treatment options, and a rising demand for effective therapeutic solutions. Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, leading to a range of neurological symptoms, including fatigue, muscle weakness, and difficulty with coordination and balance. The exact cause of MS remains unknown, but it is believed to result from an abnormal immune response that damages the myelin sheath protecting nerve fibers. As the global prevalence of MS continues to rise, there is a growing need for effective therapeutic interventions to manage symptoms and slow disease progression. This has led to significant investments in research and development, resulting in the development of a variety of treatment options, including disease-modifying therapies (DMTs), corticosteroids, and symptom management drugs. With advancements in biotechnology, the introduction of targeted therapies, biologics, and personalized medicine has also transformed the treatment landscape, offering hope for patients living with MS. The market is also being driven by the increasing number of people diagnosed with MS, particularly in developed countries where access to healthcare and diagnostic tools has improved. Furthermore, increasing government funding and support for MS research and development initiatives are expected to contribute to the market's continued growth, providing new opportunities for innovative treatment options.

According to Publisher, the global Multiple Sclerosis Therapeutics market size was valued at US$ 16660 million in 2024. With growing demand in downstream market, the Multiple Sclerosis Therapeutics is forecast to a readjusted size of US$ 19240 million by 2030 with a CAGR of 2.1% during review period. The market for multiple sclerosis therapeutics is primarily segmented by drug type, including disease-modifying therapies (DMTs), symptomatic treatments, and corticosteroids. Disease-modifying therapies (DMTs) play a central role in the treatment of MS by targeting the underlying immune system dysfunction and helping to reduce the frequency and severity of relapses, delay disease progression, and improve patients' quality of life. DMTs are further categorized into injectable, oral, and infused therapies, with the choice of treatment depending on the patient’s condition and preferences. Injectable DMTs, such as interferons and glatiramer acetate, are commonly prescribed and have been in use for several years, offering significant benefits in reducing relapse rates and slowing disease progression. However, oral therapies such as fingolimod and dimethyl fumarate have gained popularity due to their ease of administration and convenience, making them a preferred choice for many patients. Infused therapies, such as natalizumab and ocrelizumab, are typically used in patients with more severe forms of MS and are associated with higher efficacy, although they may require more frequent hospital visits for administration. Symptomatic treatments, which focus on managing the specific symptoms of MS, such as muscle spasticity, fatigue, and pain, are also an essential component of treatment regimens. These treatments include muscle relaxants, pain relievers, and medications to manage bladder and bowel dysfunction. Corticosteroids, such as methylprednisolone, are commonly used during relapses to reduce inflammation and speed up recovery from acute episodes. As research in MS continues to advance, new therapies are being developed to provide better outcomes, including therapies that target specific immune system pathways and genetic factors associated with MS, contributing to a diverse and dynamic therapeutic market.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample

In addition to segmentation by drug type, the global multiple sclerosis therapeutics market is also segmented by application, with treatment options targeting different forms of MS. Multiple sclerosis is classified into four main types: relapsing-remitting MS (RRMS), primary progressive MS (PPMS), secondary progressive MS (SPMS), and progressive-relapsing MS (PRMS). Each form of MS requires a tailored treatment approach, with relapsing-remitting MS being the most common form and accounting for a significant share of the market. Relapsing-remitting MS is characterized by flare-ups or relapses, followed by periods of remission, and patients with this type of MS are typically prescribed disease-modifying therapies to manage and reduce relapse rates. Primary progressive MS, on the other hand, involves a steady decline in function without relapses, and treatment options for this form of MS are limited. However, recent advancements in biologics, such as ocrelizumab, have shown promising results in slowing disease progression in patients with primary progressive MS, contributing to the growth of the market in this segment. Secondary progressive MS refers to a progression from relapsing-remitting MS, and patients with this form of MS may require a combination of DMTs and symptomatic treatments to manage their condition. Progressive-relapsing MS is a rare form of the disease, characterized by a steady worsening of symptoms from the onset, with occasional relapses. The development of new therapies and treatment approaches aimed at addressing these different forms of MS has resulted in a more personalized treatment approach, further driving the demand for effective therapeutics across various patient groups. As research continues, more treatments are expected to become available for these different forms of MS, expanding the therapeutic options available to patients worldwide.

The global market for multiple sclerosis therapeutics is also influenced by geographic factors, with significant differences in treatment adoption and availability across regions. North America and Europe dominate the market due to advanced healthcare infrastructure, high levels of awareness, and access to a wide range of treatment options. The United States, in particular, has a large share of the global market due to the availability of innovative therapies, reimbursement policies, and a high incidence of MS diagnoses. Additionally, the increasing number of clinical trials and research activities in these regions has led to the rapid approval and commercialization of new MS drugs. Europe, with its diverse healthcare systems and robust support for medical research, also represents a major market for MS therapeutics, with several countries implementing national strategies to improve patient care and access to treatment. In contrast, the Asia-Pacific region is experiencing rapid growth in the MS therapeutics market, driven by increasing awareness of the disease, improvements in healthcare infrastructure, and a rising prevalence of MS in countries like Japan and China. However, the market in these regions faces challenges related to affordability and access to newer therapies, which may limit the growth potential in some developing countries. Despite these challenges, the overall global market for MS therapeutics is expected to continue expanding, with a growing focus on personalized treatments, early diagnosis, and greater patient access to effective therapies. As the understanding of MS continues to improve, new therapeutic approaches and drug innovations are expected to transform the treatment landscape, offering hope for better management and improved outcomes for MS patients worldwide.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Research Analyst

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Multiple Sclerosis Therapeutics Market Size 2019-2030
2.1.2 Multiple Sclerosis Therapeutics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Multiple Sclerosis Therapeutics Segment by Type
2.2.1 Beta Interferon
2.2.2 Corticosteroids
2.2.3 Monoclonal Antibodies
2.2.4 Antineoplastic Agents
2.2.5 Others
2.3 Multiple Sclerosis Therapeutics Market Size by Type
2.3.1 Multiple Sclerosis Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Multiple Sclerosis Therapeutics Market Size Market Share by Type (2019-2024)
2.4 Multiple Sclerosis Therapeutics Segment by Distribution Channel
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 e-Commerce
2.5 Multiple Sclerosis Therapeutics Market Size by Distribution Channel
2.5.1 Multiple Sclerosis Therapeutics Market Size CAGR by Distribution Channel (2019 VS 2023 VS 2030)
2.5.2 Global Multiple Sclerosis Therapeutics Market Size Market Share by Distribution Channel (2019-2024)
3 Multiple Sclerosis Therapeutics Market Size by Player
3.1 Multiple Sclerosis Therapeutics Market Size Market Share by Players
3.1.1 Global Multiple Sclerosis Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Multiple Sclerosis Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Multiple Sclerosis Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Multiple Sclerosis Therapeutics by Regions
4.1 Multiple Sclerosis Therapeutics Market Size by Regions (2019-2024)
4.2 Americas Multiple Sclerosis Therapeutics Market Size Growth (2019-2024)
4.3 APAC Multiple Sclerosis Therapeutics Market Size Growth (2019-2024)
4.4 Europe Multiple Sclerosis Therapeutics Market Size Growth (2019-2024)
4.5 Middle East & Africa Multiple Sclerosis Therapeutics Market Size Growth (2019-2024)
5 Americas
5.1 Americas Multiple Sclerosis Therapeutics Market Size by Country (2019-2024)
5.2 Americas Multiple Sclerosis Therapeutics Market Size by Type (2019-2024)
5.3 Americas Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Multiple Sclerosis Therapeutics Market Size by Region (2019-2024)
6.2 APAC Multiple Sclerosis Therapeutics Market Size by Type (2019-2024)
6.3 APAC Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Multiple Sclerosis Therapeutics by Country (2019-2024)
7.2 Europe Multiple Sclerosis Therapeutics Market Size by Type (2019-2024)
7.3 Europe Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Multiple Sclerosis Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Type (2019-2024)
8.3 Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Multiple Sclerosis Therapeutics Market Forecast
10.1 Global Multiple Sclerosis Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Multiple Sclerosis Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Multiple Sclerosis Therapeutics Forecast
10.1.3 APAC Multiple Sclerosis Therapeutics Forecast
10.1.4 Europe Multiple Sclerosis Therapeutics Forecast
10.1.5 Middle East & Africa Multiple Sclerosis Therapeutics Forecast
10.2 Americas Multiple Sclerosis Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Multiple Sclerosis Therapeutics Market Forecast
10.2.2 Canada Multiple Sclerosis Therapeutics Market Forecast
10.2.3 Mexico Multiple Sclerosis Therapeutics Market Forecast
10.2.4 Brazil Multiple Sclerosis Therapeutics Market Forecast
10.3 APAC Multiple Sclerosis Therapeutics Forecast by Region (2025-2030)
10.3.1 China Multiple Sclerosis Therapeutics Market Forecast
10.3.2 Japan Multiple Sclerosis Therapeutics Market Forecast
10.3.3 Korea Multiple Sclerosis Therapeutics Market Forecast
10.3.4 Southeast Asia Multiple Sclerosis Therapeutics Market Forecast
10.3.5 India Multiple Sclerosis Therapeutics Market Forecast
10.3.6 Australia Multiple Sclerosis Therapeutics Market Forecast
10.4 Europe Multiple Sclerosis Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Multiple Sclerosis Therapeutics Market Forecast
10.4.2 France Multiple Sclerosis Therapeutics Market Forecast
10.4.3 UK Multiple Sclerosis Therapeutics Market Forecast
10.4.4 Italy Multiple Sclerosis Therapeutics Market Forecast
10.4.5 Russia Multiple Sclerosis Therapeutics Market Forecast
10.5 Middle East & Africa Multiple Sclerosis Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Multiple Sclerosis Therapeutics Market Forecast
10.5.2 South Africa Multiple Sclerosis Therapeutics Market Forecast
10.5.3 Israel Multiple Sclerosis Therapeutics Market Forecast
10.5.4 Turkey Multiple Sclerosis Therapeutics Market Forecast
10.5.5 GCC Countries Multiple Sclerosis Therapeutics Market Forecast
10.6 Global Multiple Sclerosis Therapeutics Forecast by Type (2025-2030)
10.7 Global Multiple Sclerosis Therapeutics Forecast by Distribution Channel (2025-2030)
11 Key Players Analysis
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Multiple Sclerosis Therapeutics Product Offered
11.1.3 Novartis Multiple Sclerosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Novartis Main Business Overview
11.1.5 Novartis Latest Developments
11.2 Teva Pharmaceuticals
11.2.1 Teva Pharmaceuticals Company Information
11.2.2 Teva Pharmaceuticals Multiple Sclerosis Therapeutics Product Offered
11.2.3 Teva Pharmaceuticals Multiple Sclerosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Teva Pharmaceuticals Main Business Overview
11.2.5 Teva Pharmaceuticals Latest Developments
11.3 Sanofi Genzyme
11.3.1 Sanofi Genzyme Company Information
11.3.2 Sanofi Genzyme Multiple Sclerosis Therapeutics Product Offered
11.3.3 Sanofi Genzyme Multiple Sclerosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Sanofi Genzyme Main Business Overview
11.3.5 Sanofi Genzyme Latest Developments
11.4 Bayer
11.4.1 Bayer Company Information
11.4.2 Bayer Multiple Sclerosis Therapeutics Product Offered
11.4.3 Bayer Multiple Sclerosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Bayer Main Business Overview
11.4.5 Bayer Latest Developments
11.5 Pfizer
11.5.1 Pfizer Company Information
11.5.2 Pfizer Multiple Sclerosis Therapeutics Product Offered
11.5.3 Pfizer Multiple Sclerosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Pfizer Main Business Overview
11.5.5 Pfizer Latest Developments
11.6 Biogen Idec
11.6.1 Biogen Idec Company Information
11.6.2 Biogen Idec Multiple Sclerosis Therapeutics Product Offered
11.6.3 Biogen Idec Multiple Sclerosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Biogen Idec Main Business Overview
11.6.5 Biogen Idec Latest Developments
11.7 Merck
11.7.1 Merck Company Information
11.7.2 Merck Multiple Sclerosis Therapeutics Product Offered
11.7.3 Merck Multiple Sclerosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Merck Main Business Overview
11.7.5 Merck Latest Developments
11.8 AbbVie
11.8.1 AbbVie Company Information
11.8.2 AbbVie Multiple Sclerosis Therapeutics Product Offered
11.8.3 AbbVie Multiple Sclerosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 AbbVie Main Business Overview
11.8.5 AbbVie Latest Developments
12 Research Findings and Conclusion

Table 1. Multiple Sclerosis Therapeutics Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Beta Interferon
Table 3. Major Players of Corticosteroids
Table 4. Major Players of Monoclonal Antibodies
Table 5. Major Players of Antineoplastic Agents
Table 6. Major Players of Others
Table 7. Multiple Sclerosis Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Multiple Sclerosis Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 9. Global Multiple Sclerosis Therapeutics Market Size Market Share by Type (2019-2024)
Table 10. Multiple Sclerosis Therapeutics Market Size CAGR by Distribution Channel (2019 VS 2023 VS 2030) & ($ Millions)
Table 11. Global Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2019-2024) & ($ Millions)
Table 12. Global Multiple Sclerosis Therapeutics Market Size Market Share by Distribution Channel (2019-2024)
Table 13. Global Multiple Sclerosis Therapeutics Revenue by Players (2019-2024) & ($ Millions)
Table 14. Global Multiple Sclerosis Therapeutics Revenue Market Share by Player (2019-2024)
Table 15. Multiple Sclerosis Therapeutics Key Players Head office and Products Offered
Table 16. Multiple Sclerosis Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Multiple Sclerosis Therapeutics Market Size by Regions 2019-2024 & ($ Millions)
Table 20. Global Multiple Sclerosis Therapeutics Market Size Market Share by Regions (2019-2024)
Table 21. Global Multiple Sclerosis Therapeutics Revenue by Country/Region (2019-2024) & ($ millions)
Table 22. Global Multiple Sclerosis Therapeutics Revenue Market Share by Country/Region (2019-2024)
Table 23. Americas Multiple Sclerosis Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 24. Americas Multiple Sclerosis Therapeutics Market Size Market Share by Country (2019-2024)
Table 25. Americas Multiple Sclerosis Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 26. Americas Multiple Sclerosis Therapeutics Market Size Market Share by Type (2019-2024)
Table 27. Americas Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2019-2024) & ($ Millions)
Table 28. Americas Multiple Sclerosis Therapeutics Market Size Market Share by Distribution Channel (2019-2024)
Table 29. APAC Multiple Sclerosis Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 30. APAC Multiple Sclerosis Therapeutics Market Size Market Share by Region (2019-2024)
Table 31. APAC Multiple Sclerosis Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 32. APAC Multiple Sclerosis Therapeutics Market Size Market Share by Type (2019-2024)
Table 33. APAC Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2019-2024) & ($ Millions)
Table 34. APAC Multiple Sclerosis Therapeutics Market Size Market Share by Distribution Channel (2019-2024)
Table 35. Europe Multiple Sclerosis Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 36. Europe Multiple Sclerosis Therapeutics Market Size Market Share by Country (2019-2024)
Table 37. Europe Multiple Sclerosis Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 38. Europe Multiple Sclerosis Therapeutics Market Size Market Share by Type (2019-2024)
Table 39. Europe Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2019-2024) & ($ Millions)
Table 40. Europe Multiple Sclerosis Therapeutics Market Size Market Share by Distribution Channel (2019-2024)
Table 41. Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 42. Middle East & Africa Multiple Sclerosis Therapeutics Market Size Market Share by Region (2019-2024)
Table 43. Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 44. Middle East & Africa Multiple Sclerosis Therapeutics Market Size Market Share by Type (2019-2024)
Table 45. Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2019-2024) & ($ Millions)
Table 46. Middle East & Africa Multiple Sclerosis Therapeutics Market Size Market Share by Distribution Channel (2019-2024)
Table 47. Key Market Drivers & Growth Opportunities of Multiple Sclerosis Therapeutics
Table 48. Key Market Challenges & Risks of Multiple Sclerosis Therapeutics
Table 49. Key Industry Trends of Multiple Sclerosis Therapeutics
Table 50. Global Multiple Sclerosis Therapeutics Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 51. Global Multiple Sclerosis Therapeutics Market Size Market Share Forecast by Regions (2025-2030)
Table 52. Global Multiple Sclerosis Therapeutics Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 53. Global Multiple Sclerosis Therapeutics Market Size Forecast by Distribution Channel (2025-2030) & ($ Millions)
Table 54. Novartis Details, Company Type, Multiple Sclerosis Therapeutics Area Served and Its Competitors
Table 55. Novartis Multiple Sclerosis Therapeutics Product Offered
Table 56. Novartis Multiple Sclerosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 57. Novartis Main Business
Table 58. Novartis Latest Developments
Table 59. Teva Pharmaceuticals Details, Company Type, Multiple Sclerosis Therapeutics Area Served and Its Competitors
Table 60. Teva Pharmaceuticals Multiple Sclerosis Therapeutics Product Offered
Table 61. Teva Pharmaceuticals Main Business
Table 62. Teva Pharmaceuticals Multiple Sclerosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 63. Teva Pharmaceuticals Latest Developments
Table 64. Sanofi Genzyme Details, Company Type, Multiple Sclerosis Therapeutics Area Served and Its Competitors
Table 65. Sanofi Genzyme Multiple Sclerosis Therapeutics Product Offered
Table 66. Sanofi Genzyme Main Business
Table 67. Sanofi Genzyme Multiple Sclerosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 68. Sanofi Genzyme Latest Developments
Table 69. Bayer Details, Company Type, Multiple Sclerosis Therapeutics Area Served and Its Competitors
Table 70. Bayer Multiple Sclerosis Therapeutics Product Offered
Table 71. Bayer Main Business
Table 72. Bayer Multiple Sclerosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 73. Bayer Latest Developments
Table 74. Pfizer Details, Company Type, Multiple Sclerosis Therapeutics Area Served and Its Competitors
Table 75. Pfizer Multiple Sclerosis Therapeutics Product Offered
Table 76. Pfizer Main Business
Table 77. Pfizer Multiple Sclerosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 78. Pfizer Latest Developments
Table 79. Biogen Idec Details, Company Type, Multiple Sclerosis Therapeutics Area Served and Its Competitors
Table 80. Biogen Idec Multiple Sclerosis Therapeutics Product Offered
Table 81. Biogen Idec Main Business
Table 82. Biogen Idec Multiple Sclerosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 83. Biogen Idec Latest Developments
Table 84. Merck Details, Company Type, Multiple Sclerosis Therapeutics Area Served and Its Competitors
Table 85. Merck Multiple Sclerosis Therapeutics Product Offered
Table 86. Merck Main Business
Table 87. Merck Multiple Sclerosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 88. Merck Latest Developments
Table 89. AbbVie Details, Company Type, Multiple Sclerosis Therapeutics Area Served and Its Competitors
Table 90. AbbVie Multiple Sclerosis Therapeutics Product Offered
Table 91. AbbVie Main Business
Table 92. AbbVie Multiple Sclerosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 93. AbbVie Latest Developments

Figure 1. Multiple Sclerosis Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Multiple Sclerosis Therapeutics Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Multiple Sclerosis Therapeutics Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Multiple Sclerosis Therapeutics Sales Market Share by Country/Region (2023)
Figure 8. Multiple Sclerosis Therapeutics Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Multiple Sclerosis Therapeutics Market Size Market Share by Type in 2023
Figure 10. Multiple Sclerosis Therapeutics in Hospital Pharmacies
Figure 11. Global Multiple Sclerosis Therapeutics Market: Hospital Pharmacies (2019-2024) & ($ Millions)
Figure 12. Multiple Sclerosis Therapeutics in Retail Pharmacies
Figure 13. Global Multiple Sclerosis Therapeutics Market: Retail Pharmacies (2019-2024) & ($ Millions)
Figure 14. Multiple Sclerosis Therapeutics in e-Commerce
Figure 15. Global Multiple Sclerosis Therapeutics Market: e-Commerce (2019-2024) & ($ Millions)
Figure 16. Global Multiple Sclerosis Therapeutics Market Size Market Share by Distribution Channel in 2023
Figure 17. Global Multiple Sclerosis Therapeutics Revenue Market Share by Player in 2023
Figure 18. Global Multiple Sclerosis Therapeutics Market Size Market Share by Regions (2019-2024)
Figure 19. Americas Multiple Sclerosis Therapeutics Market Size 2019-2024 ($ Millions)
Figure 20. APAC Multiple Sclerosis Therapeutics Market Size 2019-2024 ($ Millions)
Figure 21. Europe Multiple Sclerosis Therapeutics Market Size 2019-2024 ($ Millions)
Figure 22. Middle East & Africa Multiple Sclerosis Therapeutics Market Size 2019-2024 ($ Millions)
Figure 23. Americas Multiple Sclerosis Therapeutics Value Market Share by Country in 2023
Figure 24. United States Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 25. Canada Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 26. Mexico Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 27. Brazil Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 28. APAC Multiple Sclerosis Therapeutics Market Size Market Share by Region in 2023
Figure 29. APAC Multiple Sclerosis Therapeutics Market Size Market Share by Type in 2023
Figure 30. APAC Multiple Sclerosis Therapeutics Market Size Market Share by Distribution Channel in 2023
Figure 31. China Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 32. Japan Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 33. Korea Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 34. Southeast Asia Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 35. India Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 36. Australia Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 37. Europe Multiple Sclerosis Therapeutics Market Size Market Share by Country in 2023
Figure 38. Europe Multiple Sclerosis Therapeutics Market Size Market Share by Type (2019-2024)
Figure 39. Europe Multiple Sclerosis Therapeutics Market Size Market Share by Distribution Channel (2019-2024)
Figure 40. Germany Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 41. France Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 42. UK Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 43. Italy Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 44. Russia Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 45. Middle East & Africa Multiple Sclerosis Therapeutics Market Size Market Share by Region (2019-2024)
Figure 46. Middle East & Africa Multiple Sclerosis Therapeutics Market Size Market Share by Type (2019-2024)
Figure 47. Middle East & Africa Multiple Sclerosis Therapeutics Market Size Market Share by Distribution Channel (2019-2024)
Figure 48. Egypt Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 49. South Africa Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 50. Israel Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 51. Turkey Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 52. GCC Country Multiple Sclerosis Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 53. Americas Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 54. APAC Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 55. Europe Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 56. Middle East & Africa Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 57. United States Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 58. Canada Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 59. Mexico Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 60. Brazil Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 61. China Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 62. Japan Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 63. Korea Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 64. Southeast Asia Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 65. India Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 66. Australia Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 67. Germany Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 68. France Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 69. UK Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 70. Italy Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 71. Russia Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 72. Spain Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 73. Egypt Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 74. South Africa Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 75. Israel Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 76. Turkey Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 77. GCC Countries Multiple Sclerosis Therapeutics Market Size 2025-2030 ($ Millions)
Figure 78. Global Multiple Sclerosis Therapeutics Market Size Market Share Forecast by Type (2025-2030)
Figure 79. Global Multiple Sclerosis Therapeutics Market Size Market Share Forecast by Distribution Channel (2025-2030)

Related Reports

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted